M&A / Deals Heart drug biotech Kardigan raises $400m in upscaled IPO PharmaphorumCardiovascular drug developer Kardigan has completed its IPO, raising substantially more than it originally anticipated.CardiovascularRead full story pharminent June 18, 2026 (Last updated: June 18, 2026) Pharmaphorum Cardiovascular drug developer Kardigan has completed its IPO, raising substantially more than it originally anticipated. Cardiovascular Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Cardio biotech Kardigan binds off $400M upsized IPONext: New biotech cAMPfield emerges with $180M to reshape IBD treatment Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
